Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Non-Randomized, Open-label, Multi-centre Study of the Safety and Efficacy of Tebentafusp in Melanoma With Molecular Relapsed Disease

NCT05315258 is registered in ClinicalTrials.gov with University of Oxford as lead sponsor.

NCT NCT05315258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05315258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Non-Randomized, Open-label, Multi-centre Study of the Safety and Efficacy of Tebentafusp in Melanoma With Molecular Relapsed Disease
Lead sponsor
University of Oxford
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 25, 2022
Completion date
June 30, 2027
Enrollment
850 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin), melanoma, uveal